topic

838 Oncolytic virus induced tumour-infiltrating lymphocytes (TILs) for the treatment of colorectal cancer
Sydney Vallati, Mathieu Crupi, Zaid Taha, Julia Petryk, Bradley Austin, Victoria Gilchrist, Nouf Alluqmani, Stephen Boulton, John Bell

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A936; DOI: 10.1136/jitc-2023-SITC2023.0838
839 TALL^TM (Targeted Antigen Loaded Liposomes) immunotherapy exploits recall immunity to form an excellent co-therapy option for immune checkpoint inhibitors
Indu Venugopal, Morgan N DeLong, Amanda G Powell, Shelby Knoche, Michael J McGuire, Kathlynn C Brown

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A937; DOI: 10.1136/jitc-2023-SITC2023.0839
840 Abstract withdrawn
Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A938; DOI: 10.1136/jitc-2023-SITC2023.0840
841 LBL-019, a novel TNFR2 agonist antibody, shows potent anti-tumor efficacy through preferentially activating CD8+ T cells and alleviating the suppressive effect of Treg cells
Baohui Wang, Hailin Wang, Tingting Li, Jianming Sun, Xiao Huang, Huan Lin, Yujia Dan, Yurong Qin, Peng Zhang, Jing Guan, Guojin Wu, Xiaofan Hou, Shoupeng Lai, Xiaoqiang Kang, Hong Ling

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A939; DOI: 10.1136/jitc-2023-SITC2023.0841
842 High-throughput screening of cancer immunotherapy combinations using a hydrogel-based 3D in vitro tumor platform
Bin Xue, Julia Schüler, Christopher Harrod, Kolin Hribar

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A940; DOI: 10.1136/jitc-2023-SITC2023.0842
843 Intra-cerebral spinal fluid vaccination to facilitate antigen-specific T-cell responses in the CNS tumors
Akane Yamamichi, Su Phyu, Tiffany Chen, Akinari Kazuyoshi, Naozumi Harada, Hideho Okada

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A941; DOI: 10.1136/jitc-2023-SITC2023.0843
844 Synergistic effects of mediated gene therapy with GEN2(HSV-TK) and GEN1018(mIL-12) in an experimental model of colorectal cancer
Joshua Yang, Cecilia Roh, Jacqueline Fischer-Lougheed, Lauren Slowskei, Hu Zhang, Joseph McNulty, Robert Johnson

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A942; DOI: 10.1136/jitc-2023-SITC2023.0844
845 ABL503 (TJ-L14B), PD-L1×4–1BB bispecific antibody, reinvigorates exhausted tumor-infiltrating CD8⁺ T cells and synergizes with PD-1 blockade
Gihoon You, Seung Hyuck Jeon, Kyungjin Park, Hyunjoo Kim, Jaehyoung Jeon, Youngkwang Kim, Claire Xu, Xuejun Liu, Su-Hyung Park, Jaeho Jung

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A943; DOI: 10.1136/jitc-2023-SITC2023.0845
846 Myeloid reprogramming by JAK inhibition enhances checkpoint blockade immunotherapy
Jaroslav Zak, Isaraphorn Pratumchai, Brett S Marro, Kristi L Marquardt, Michael BA Oldstone, Judith A Varner, Veronika Bachanova, John R Teijaro

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A944; DOI: 10.1136/jitc-2023-SITC2023.0846
847 Optimal dose selection of ADG126 (a masked anti-CTLA-4 SAFEbody®) with significantly widened therapeutic index compared to ipilimumab in combination with anti-PD-1 antibodies informed by QSP modeling
Songmao Zheng, Meng Sun, Xin Wang, John J Skinner, Guizhong Liu, Kristine She, Jiangchun Xu, Felix Du, Yan Li, Jiping Zha, Peter Luo

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A945; DOI: 10.1136/jitc-2023-SITC2023.0847

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages